In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Tandem Diabetes Care Inc (NASDAQ: TNDM) was $41.12 for the day, down -1.56% from the previous closing price of $41.77. In other words, the price has decreased by -$1.56 from its previous closing price. On the day, 0.74 million shares were traded. TNDM stock price reached its highest trading level at $42.05 during the session, while it also had its lowest trading level at $40.86.
Ratios:
Our analysis of TNDM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 3.05. In the meantime, Its Debt-to-Equity ratio is 2.04 whereas as Long-Term Debt/Eq ratio is at 1.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on August 22, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $45.
On August 08, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $57.
On May 30, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $60.Redburn Atlantic initiated its Buy rating on May 30, 2024, with a $60 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 30 ’24 when Allen Dick sold 5,000 shares for $51.68 per share. The transaction valued at 258,400 led to the insider holds 0 shares of the business.
Allen Dick bought 5,000 shares of TNDM for $94,778 on Nov 27 ’23. The Director now owns 19,962 shares after completing the transaction at $18.96 per share. On Nov 08 ’23, another insider, Vosseller Leigh, who serves as the EVP & CHIEF FINANCIAL OFFICER of the company, bought 6,200 shares for $15.39 each. As a result, the insider paid 95,395 and bolstered with 11,860 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 2691916544 and an Enterprise Value of 2759168000. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.38 while its Price-to-Book (P/B) ratio in mrq is 11.50. Its current Enterprise Value per Revenue stands at 3.466 whereas that against EBITDA is -20.15.
Stock Price History:
Over the past 52 weeks, TNDM has reached a high of $53.69, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is -1.78%, while the 200-Day Moving Average is calculated to be 19.35%.
Shares Statistics:
TNDM traded an average of 1.60M shares per day over the past three months and 1024550 shares per day over the past ten days. A total of 65.55M shares are outstanding, with a floating share count of 64.94M. Insiders hold about 0.80% of the company’s shares, while institutions hold 113.83% stake in the company. Shares short for TNDM as of 1723680000 were 10522918 with a Short Ratio of 6.56, compared to 1721001600 on 10969930. Therefore, it implies a Short% of Shares Outstanding of 10522918 and a Short% of Float of 24.92.
Earnings Estimates
At present, 17.0 analysts are actively evaluating the performance of Tandem Diabetes Care Inc (TNDM) in the stock market.The consensus estimate for the next quarter is -$0.19, with high estimates of $0.02 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.38 and -$1.96 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.18, with 19.0 analysts recommending between -$0.84 and -$1.54.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 17 analysts. It ranges from a high estimate of $224.9M to a low estimate of $222.1M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $192.71MFor the next quarter, 17 analysts are estimating revenue of $251.38M. There is a high estimate of $253.84M for the next quarter, whereas the lowest estimate is $248.5M.
A total of 19 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $916.9M, while the lowest revenue estimate was $885.2M, resulting in an average revenue estimate of $890.8M. In the same quarter a year ago, actual revenue was $747.72MBased on 19 analysts’ estimates, the company’s revenue will be $995.63M in the next fiscal year. The high estimate is $1.11B and the low estimate is $960.9M.
